• Inventiva flagged two new poster abstracts on lanifibranor for EASL Congress 2026 in Barcelona, with presentations scheduled for May 29 and May 30, 2026.
• One analysis is set to argue that improvements in liver tissue measures and cardiometabolic markers in MASH occur regardless of weight change, with effects closely tied to adiponectin induction.
• Another study is slated to show lanifibranor modulates changes in liver sinusoidal endothelial cell structure linked to metabolic-dysfunction associated steatotic liver disease.
• Lanifibranor remains Inventiva’s lead oral drug candidate, now in Phase 3 NATiV3 for adult MASH, with FDA Breakthrough Therapy and Fast Track designations supporting its regulatory strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130230OMX_____CNEWS_FR_GNW1001181665_fr) on May 13, 2026, and is solely responsible for the information contained therein.